Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5B

被引:5
|
作者
Xiao, Dong [1 ]
Dai, Xing [1 ]
Liu, Hong [1 ]
He, Shuwen [1 ]
Shi, Zhi-Cai [1 ]
Ludmerer, Steven W. [2 ]
Li, Fangbiao [3 ]
Nargund, Ravi [1 ]
Palani, Anandan [1 ]
机构
[1] Merck & Co Inc, Dept Med Chem, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA
[2] Merck & Co Inc, Dept Biol, 770 Sumneytown Pike, West Point, PA 19486 USA
[3] Merck & Co Inc, Dept Drug Metab, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA
关键词
NS5B NNI inhibitors; Lead optimization; Multi-step parallel libraries; Pan-genotypic potency; HEPATITIS-C VIRUS; MEDICINAL CHEMISTS; DISCOVERY; EPIDEMIOLOGY; POLYMERASE; INFECTION;
D O I
10.1016/j.bmcl.2020.127004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In a lead optimization effort towards NS5B NNI inhibitors, two multi-step parallel libraries were designed and successfully synthesized. Through this effort we discovered compound 9B, which achieved rigorous and delicate balance of inhibition across the common genotypes and mutants with < 10 nM potency. In addition, the bicyclic compounds 9B exhibited improved FASSIF solubility over the tetracyclic compound MK-8876. This strategic approach demonstrated that, even within limited reaction scope, multi-step parallel libraries could provide access to more complex chemical space. This expedient access facilitates diverse, purpose-driven optimization of SAR and physicochemical properties.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Phase 1 study assessing the safety, pharmacokinetics, and antiviral activity of CC-31244, a pan-genotypic, potent non-nucleoside NS5B polymerase inhibitor for the treatment of hepatitis C virus infection
    Lee, S.
    Pascual, L.
    Pattassery, J.
    Sulkowski, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S720 - S720
  • [32] The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function
    Hebner, Christy M.
    Han, Bin
    Brendza, Katherine M.
    Nash, Michelle
    Sulfab, Maisoun
    Tian, Yang
    Hung, Magdeleine
    Fung, Wanchi
    Vivian, Randall W.
    Trenkle, James
    Taylor, James
    Bjornson, Kyla
    Bondy, Steven
    Liu, Xiaohong
    Link, John
    Neyts, Johan
    Sakowicz, Roman
    Zhong, Weidong
    Tang, Hengli
    Schmitz, Uli
    PLOS ONE, 2012, 7 (06):
  • [33] Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: Synthesis and optimization studies of benzothiazine-substituted tetramic acids
    de Vicente, Javier
    Hendricks, Robert T.
    Smith, David B.
    Fell, Jay B.
    Fischer, John
    Spencer, Stacey R.
    Stengel, Peter J.
    Mohr, Peter
    Robinson, John E.
    Blake, James F.
    Hilgenkamp, Ramona K.
    Yee, Calvin
    Zhao, Junping
    Elworthy, Todd R.
    Tracy, Jahari
    Chin, Elbert
    Li, Jim
    Lui, Al
    Wang, Beihan
    Oshiro, Connie
    Harris, Seth F.
    Ghate, Manjiri
    Leveque, Vincent J. P.
    Najera, Isabel
    Le Pogam, Sophie
    Rajyaguru, Sonal
    Ao-Ieong, Gloria
    Alexandrova, Ludmila
    Fitch, Bill
    Brandl, Michael
    Masjedizadeh, Mohammad
    Wu, Shao-yong
    de Keczer, Steve
    Voronin, Tatyana
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (19) : 5648 - 5651
  • [34] Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase
    Sofia, Michael J.
    Chang, Wonsuk
    Furman, Phillip A.
    Mosley, Ralph T.
    Ross, Bruce S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (06) : 2481 - 2531
  • [35] Structure-based optimization and derivatization of 2-substituted quinolone-based non-nucleoside HCV NS5B inhibitors with submicromolar cellular replicon potency
    Cheng, Yu
    Shen, Jian
    Peng, Run-Ze
    Wang, Gui-Feng
    Zuo, Jian-Ping
    Long, Ya-Qiu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (12) : 2900 - 2906
  • [36] PRECLINICAL PHARMACOKINETIC AND ADME CHARACTERIZATION OF VCH-222, A NOVEL NON-NUCLEOSIDE HCV NS5B POLYMERASE INHIBITOR
    Chauret, N.
    Chagnon-Labelle, C.
    Diallo, M.
    Laquerre, J.
    Laterreur, J.
    May, S.
    Ste-Marie, L.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S341 - S342
  • [37] Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition
    Biswal, Bichitra K.
    Wang, Meitian
    Cherney, Maia M.
    Chan, Laval
    Yannopoulos, Constantin G.
    Bilimoria, Darius
    Bedard, Jean
    James, Michael N. G.
    JOURNAL OF MOLECULAR BIOLOGY, 2006, 361 (01) : 33 - 45
  • [38] Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase
    Kukolj, G
    McGibbon, GA
    McKercher, G
    Marquis, M
    Lefèbvre, S
    Thauvette, L
    Gauthier, J
    Goulet, S
    Poupart, MA
    Beaulieu, PL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (47) : 39260 - 39267
  • [39] Design, synthesis, assessment, and molecular docking of novel pyrrolopyrimidine (7-deazapurine) derivatives as non-nucleoside hepatitis C virus NS5B polymerase inhibitors
    Mohamed, Mosaad S.
    Sayed, Amira I.
    Khedr, Mohammed A.
    Soror, Sameh H.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (09) : 2146 - 2157
  • [40] Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients
    Le Pogam, Sophie
    Seshaadri, Amritha
    Kosaka, Alan
    Chiu, Sophie
    Kang, Hyunsoon
    Hu, Steven
    Rajyaguru, Sonal
    Symons, Julian
    Cammack, Nick
    Najera, Isabel
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (06) : 1205 - 1216